Accuray Inc. has announced its financial results for the first quarter of fiscal 2027, revealing a 4% growth in service revenue. This development is significant for the company as it reflects its ongoing transformation and efforts to enhance operational efficiency. The results are particularly important in the context of the surgical and medical instruments industry, where competition is intensifying.

The company reported its earnings on November 4, 2026, with key highlights indicating a positive trajectory. Service revenue reached $59.2 million, with a 5% increase on a constant currency basis. This growth was attributed to service contract pricing actions and nearly 3% growth in the global installed base.

Accuray's service gross margin also saw an improvement, rising 120 basis points to 35.1%, largely due to effective pricing strategies and a lower service labor cost structure. Operating expenses for the quarter were reported at $62.6 million, which included a non-cash goodwill impairment charge of $35.4 million. Excluding this charge, operating expenses fell 29% year-over-year, demonstrating the impact of the company’s transformation initiatives.

In addition to financial metrics, Accuray highlighted its strategic partnerships as a key driver of future growth. The company signed a definitive agreement with RaySearch to accelerate its online adaptive radiation therapy strategy and advanced its collaboration with Samsung NeuroLogica on volumetric imaging for the CyberKnife System. These partnerships are expected to enhance Accuray's offerings and position it favorably in the competitive landscape.

Steve La Neve, President and CEO, emphasized the importance of execution in fiscal 2027, stating, "During the first quarter, we made progress across several areas. Service margins improved, operating expenses remained well controlled, we strengthened our financial position, and we advanced our innovation roadmap through strategic partnerships with RaySearch and Samsung NeuroLogica." He also noted the opportunity to improve product and order performance, driven by customer engagement and growing clinical evidence supporting precision radiation therapy.

The filing also mentioned a $15 million investment associated with a financing transaction with TCW, aimed at reducing leverage and enhancing liquidity. Following the quarter's end, stockholders approved proposals to facilitate a $40 million exchange of term loan debt for convertible preferred equity, which is expected to provide greater flexibility for executing the company’s strategy.

As Accuray moves forward, it will continue to focus on enhancing its financial position and operational efficiency. The company’s results and strategic direction may influence its competitors in the surgical and medical instruments industry as they adapt to evolving market conditions.

Details on future actions were not specified in the filing. For more information, the company’s press release and earnings call presentation are available on its Investor Relations website.